Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Friday. They currently have a $9.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 65.14% from the company’s current price.
Separately, BidaskClub lowered Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 26th. Four investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $9.00.
Pieris Pharmaceuticals (NASDAQ PIRS) traded up $0.20 during trading hours on Friday, reaching $5.45. The company had a trading volume of 639,100 shares, compared to its average volume of 358,395. Pieris Pharmaceuticals has a 1 year low of $1.34 and a 1 year high of $6.58.
Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative return on equity of 180.85% and a negative net margin of 321.83%. The firm had revenue of $3.93 million for the quarter, compared to analyst estimates of $1.52 million. Pieris Pharmaceuticals’s revenue was up 400.3% on a year-over-year basis. analysts anticipate that Pieris Pharmaceuticals will post -0.83 EPS for the current year.
In related news, insider Allan Reine purchased 65,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was acquired at an average price of $4.82 per share, for a total transaction of $313,300.00. Following the transaction, the insider now directly owns 45,000 shares of the company’s stock, valued at approximately $216,900. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James A. Geraghty purchased 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was bought at an average price of $4.82 per share, with a total value of $48,200.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at $48,200. The disclosure for this purchase can be found here. Company insiders own 4.05% of the company’s stock.
Several large investors have recently added to or reduced their stakes in PIRS. State Street Corp acquired a new position in shares of Pieris Pharmaceuticals in the 2nd quarter valued at $2,377,000. Northern Trust Corp acquired a new position in shares of Pieris Pharmaceuticals in the 2nd quarter valued at $1,625,000. Renaissance Technologies LLC acquired a new stake in Pieris Pharmaceuticals during the 1st quarter worth about $661,000. TIAA CREF Investment Management LLC acquired a new stake in Pieris Pharmaceuticals during the 2nd quarter worth about $649,000. Finally, Vanguard Group Inc. acquired a new stake in Pieris Pharmaceuticals during the 2nd quarter worth about $526,000. Institutional investors and hedge funds own 50.87% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.